Stock Symbol GILD Investor Relations and Analyst Views

GILD is a well-established pharmaceutical company with a strong presence in the industry.

GILD's stock symbol is widely recognized and traded on various stock exchanges.

Analysts closely follow GILD's financial performance and provide valuable insights to investors.

GILD's financial reports reveal a steady revenue growth over the years, with a significant increase in 2020.

GILD's research and development efforts are focused on creating innovative treatments for various diseases.

The company's commitment to improving healthcare outcomes has earned it a reputation as a leader in the pharmaceutical industry.

Take a look at this: Brighthouse Financial Stock Symbol

Gilead Sciences' revenue decreased by 0.60% in 2023 to $27.12 billion.

The company's earnings were $5.67 billion, a significant increase of 23.37% compared to the previous year.

Gilead Sciences' current share price is $97.20, with a 52-week high of $98.90 and a low of $62.07. The 1-year change is 26.71%.

Here are the estimated revenue and earnings per share (EPS) for Gilead Sciences from 2025 to 2028:

The number of analysts estimating Gilead Sciences' earnings and revenue varies, but the average estimates are $7.597 USD and $28,485 USD for 2025, respectively.

Gilead Sciences's revenue decreased by 0.60% in 2023 compared to the previous year, reaching $27.12 billion.

The company's earnings, however, saw a significant increase of 23.37% to $5.67 billion in 2023.

Here are some key financial performance metrics for Gilead Sciences:

Gilead Sciences is expected to see significant revenue growth in the coming years, with estimates suggesting that revenue will reach $32.209 billion by 2028.

Here's a breakdown of the company's estimated revenue and earnings for the next few years:

Gilead Sciences has a consistent dividend payment history, with payments made every year since 2005. The company's dividend payments have varied over the years, with the highest payment made in 2020 at $2.72.

The dividend yield, which is the ratio of the annual dividend payment to the stock's current price, has also fluctuated. In 2019, the dividend yield was 3.88%, while in 2023 it was 3.70%.

Here is a breakdown of Gilead Sciences' dividend payments and yields over the past few years:

Gilead Sciences has consistently paid a dividend since 2005, with the exception of 2014 and 2013, when no dividend was paid.

GILD's investor relations team is dedicated to providing timely and accurate information to the investment community.

The company's quarterly earnings reports are released on the first Wednesday of each quarter, and can be accessed on their investor relations website.

GILD's investor relations team is available to answer questions and provide additional information to investors.

The company's investor relations website features a calendar of upcoming events, including earnings calls and investor conferences.

GILD's investor relations team can be contacted through the website's contact form or by phone.

The company's investor relations team is committed to maintaining transparency and keeping investors informed about company developments.

Recommended read: Stock Symbol B

Analysts are overwhelmingly bullish on GILD stock, with 26 analysts giving it an average rating of "Buy".

The 12-month stock price forecast is a significant increase of 1.42% from the latest price, with a predicted value of $98.58.

The Barchart Technical Opinion rating is a strong 100% Buy, indicating that the current trend is likely to continue.

Beware of a trend reversal, as the market is in highly overbought territory, which can be a sign of a potential shift in direction.

Long-term indicators fully support a continuation of the trend, suggesting that analysts are confident in GILD's future performance.

Recommended read: History of Stock Price Symbol Svm

Gilead Sciences, Inc. (GILD) frequently participates in industry conferences to share updates and insights with investors and analysts.

The company's leadership, including Daniel O'Day, Chairman and Chief Executive Officer, and Johanna Mercier, have been part of these conferences.

Gilead Sciences, Inc. (GILD) has held conferences with firms such as JPMorgan and Evercore ISI, highlighting the company's commitment to staying connected with the investment community.

These conferences often provide a platform for the company's Chief Financial Officer, Andrew Dickinson, to share financial insights and updates.

The JPMorgan Healthcare Conference is a significant event where industry leaders share their insights and updates. Gilead Sciences, Inc. (GILD) has participated in this conference.

Gilead Sciences, Inc. (GILD) has a presence at the JPMorgan Annual Healthcare Conference. The company's Chairman and Chief Executive Officer, Daniel O'Day, and Johanna Mercier, a company participant, have been part of the conference.

The conference call for Gilead Sciences, Inc. (GILD) took place on January 13, 2025, at 2:15 PM ET. The company's participation in the conference is a testament to its commitment to the healthcare industry.

For your interest: Change Healthcare Stock Symbol

The JPMorgan Annual Healthcare Conference is a premier event that brings together industry leaders and experts. Gilead Sciences, Inc. (GILD) is one of the companies that has taken part in this event.

The conference provides a platform for companies like Gilead Sciences, Inc. (GILD) to share their updates and insights with the audience. The event is a valuable opportunity for the company to connect with investors and industry stakeholders.

Suggestion: Ticker Symbol and Stock Exchange for Given Company Neximmune Inc

The Evercore ISI HealthCONx Conference is a notable event in the healthcare industry. Gilead Sciences, Inc. (GILD) has participated in this conference.

The conference took place on December 4, 2024, at 11:40 AM ET. Andrew Dickinson, Chief Financial Officer of Gilead Sciences, Inc., represented the company.

The conference is an opportunity for industry leaders to share insights and updates.